Navigation Links
Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Date:12/21/2009

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
2. Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
3. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
4. Bioheart, Inc. Announces Additional Funding Support
5. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
6. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
7. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
8. Bioheart, Inc. Announces Results of Annual Meeting
9. Bioheart, Inc., Announces Management Change
10. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
11. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Hussey Copper , a leader in ... copper announces Pullman Regional Hospital,s conversion of more than ... touch surface, at a nominal cost.  This reasonably priced ... other bacteria within 2 hours of exposure 1 and ... infectious diseases in its facilities. Pullman Regional ...
(Date:7/22/2014)... Quorum Review IRB, the industry leader in central ... called Quick Step™ . The offering went live on ... industry’s need for seamless study start-up with a large volume ... planning 50 or more North American investigator sites, as well ... count of 80 or more. Qualifying studies may also enroll ...
(Date:7/22/2014)... July 22, 2014 Biofeedback ... disorder (ADHD) is diagnosed, selecting medication to best treat ... Analyzing brain patterns by using electroencephalography (EEG) can help ... thus lower the risk of adverse drug events. , ... Biomarkers” in the current issue of the journal ...
(Date:7/21/2014)... Hills, IL (PRWEB) July 21, 2014 ... control, and simple programming, the new Cole-Parmer® ... Head is easy to operate for automated ... cycles for hands-free dispensing. The batch count function ... cumulative volume or totalizer tracks amount dispensed across ...
Breaking Biology Technology:Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2
... E May Help,Prevent, Cardiovascular Events in Hp2-2 Diabetes, ... SYI ) today announced new data demonstrating that,discontinuation ... may result,in an increased risk of heart attack and ... at the Annual Scientific,Sessions of the American Heart Association, ...
... First laboratory to be certified for A1c testing using ... Heritage Labs,International LLC, a division of Hooper Holmes ... A1c testing methods by the National,Glycohemoglobin Standardization Program (NGSP)., ... hemoglobin A1c, one,for testing whole blood specimens and the ...
... 11 Amicus Therapeutics,(Nasdaq: FOLD ), today announced ... at the 5th Annual Lazard Capital Markets Healthcare,Conference in ... p.m. EST., A webcast and audio archive of ... at http://www.amicustherapeutics.com . Participants,should allow approximately five to ...
Cached Biology Technology:Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 2Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 3Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting 4Heritage Labs Announces A1c Test Certification Milestone 2Heritage Labs Announces A1c Test Certification Milestone 3
(Date:7/22/2014)... by researchers in modifying properties of nanomaterials for application ... thanks to recent innovative studies conducted by scientists from ... use of a simple, efficient and low cost technique ... led by Professor Sow Chorng Haur from the Department ... that the properties of two different types of materials ...
(Date:7/22/2014)... a cost-effectiveness analysis of commercial diet programs and pills, ... the best value for the money. The Jenny Craig ... the most expensive option tested, according to researchers at ... The findings, published in the June issue of the ... health and weight-loss benefits per dollar spent as insurance ...
(Date:7/22/2014)... multinational, collaborative effort, researchers from the Icahn School of ... locations in the human genome associated with the risk ... on any psychiatric disorder to date, conducted with 80,000 ... point to biological mechanisms and pathways that may underlie ... the disorder, which has seen little innovation in drug ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3
... have determined the fine-scale genetic structure of the first ... change. , They used a high-throughput sequencing technique called ... , Their results, which focus on the pitcher ... the journal Proceedings of the National Academy of ...
... of the High Arctic climate roughly 50 million years ago ... explain how ancient alligators and giant tortoises were able to ... as they endured six months of darkness each year. ... Eocene period 52 to 53 million years ago, also has ...
... Male infertility is a common medical problem, affecting millions ... include an inability to make productive sperm. Now, using ... of Pennsylvania School of Medicine are beginning to identify ... problem. Shelley Berger PhD, the Daniel S. ...
Cached Biology News:Genetic structure of first animal to show evolutionary response to climate change determined 2Genetic structure of first animal to show evolutionary response to climate change determined 3New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 2New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 3New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 4Swimming upstream: Molecular approaches to better understand male infertility 2Swimming upstream: Molecular approaches to better understand male infertility 3
... GeneBLAzer cell-based assays utilize the membrane-permeant ... the negatively charged fluorescent beta-lactamase substrates, ... readily enter the cell, where cleavage ... them into their negatively charged forms, ...
Chlorine-36, 3.7 MBq, 100 uCi. 0.1-0.3 HCl.< 111 MBq/g Cl, < 3 mCi/g Cl.Dispensed to order. Please inquire for alternative pack sizes. Category: Radiochemicals &Radiation Safety, Radiochemicals....
Src cDNA Expression Kit (wild type)...
... Detection Kit is intended for quantitative detection ... peptides, which can result from the gradual, ... aspartic acid residues during storage or handling. ... the monitoring of charge differences for detection, ...
Biology Products: